The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats

BACKGROUND: The advent of proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting drugs have provided an effective, but extremely expensive treatment for the management of low density lipoprotein (LDL). Our aim was to explore a cost-effective application of camelid anti-PCSK9 single domain...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Transl Med
Prif Awduron: Li, Xinyang, Wang, Meiniang, Zhang, Xinhua, Liu, Chuxin, Xiang, Haitao, Huang, Mi, Ma, Yingying, Gao, Xiaoyan, Jiang, Lin, Liu, Xiaopan, Li, Bo, Hou, Yong, Zhang, Xiuqing, Yang, Shuang, Yang, Naibo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2020
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7018876/
https://ncbi.nlm.nih.gov/pubmed/32056048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-020-0265-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg